Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3: LY4268989 for moderately to severely active ulcerative colitis
2025-524404-29-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LY4268989 with Placebo (2 arms). Primary endpoints: Percentage of participants who achieve clinical remission with modified Mayo score and Percentage of participants who achieve clinical remission with modified Mayo score among Week 10 responders. Planned start Jun 2026; status: authorised.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-524404-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524404-29-00.